Written by the Nuvirox Research Team
Key Points
- A 12-week randomized trial in obese, insulin-resistant men found NR raised NAD+ levels but did not significantly improve insulin sensitivity.
- A related trial measuring pancreatic beta-cell and incretin hormone function in similar men also found no meaningful benefit despite NAD+ metabolome changes.
- Nearly all positive glucose-control data for NAD+ precursors comes from mouse models of diabetes, not humans — a gap worth being clear-eyed about.
Short answer: in the human trial that most closely resembles a type 2 diabetes profile — obese, insulin-resistant men — nicotinamide riboside raised NAD+ levels but did not significantly improve insulin sensitivity. The animal data is much more encouraging than the human data, and that gap matters if you're deciding whether this is relevant to your own blood sugar management.
Why is there a diabetes hypothesis for NAD+ at all?
In mouse models, nicotinamide riboside meaningfully improved glucose tolerance, reduced fasting blood glucose, and protected against diabetic neuropathy in both prediabetic and type-2-diabetic animals. The proposed mechanism runs through NAD+-dependent sirtuins, which regulate glucose and lipid metabolism, plus improvements in mitochondrial function in liver and muscle tissue. It's a genuinely well-studied pathway — in rodents.
What happened when this was tested in humans?
The key trial here (Dollerup et al., 2018, American Journal of Clinical Nutrition) enrolled obese, insulin-resistant men — a population chosen specifically because it mirrors prediabetic and early type 2 diabetic physiology — and gave them NR for 12 weeks in a randomized, placebo-controlled design. The study confirmed NR was safe and meaningfully increased NAD+ metabolites in blood and muscle. But on the outcomes that actually matter for diabetes risk — insulin sensitivity, hepatic fat, and related metabolic markers — the trial did not find a significant improvement over placebo.
A related follow-up trial from the same broader research group (Dollerup et al., 2019, Journal of Clinical Endocrinology & Metabolism) dug deeper into pancreatic function, testing whether NR (1,000 mg twice daily for 12 weeks) affected beta-cell function, alpha-cell function, and incretin hormone secretion in 40 men with obesity and insulin resistance. This was a more granular look at exactly the machinery that fails in type 2 diabetes — again, without the clear benefit the rodent data would predict.
Is there any positive human signal at all?
Yes, though it's smaller and less directly relevant to diagnosed diabetes. A short 7-day pilot trial of a nicotinamide/D-ribose combination (not NR specifically) in healthy middle-aged adults found a statistically significant reduction in blood glucose without a corresponding change in insulin secretion — interpreted by the researchers as a possible improvement in insulin sensitivity or glucose tolerance. This was a small, short, non-diabetic-population study, and it used a different NAD+ precursor combination than what's in most modern NR supplements. It's a data point, not a resolution.
A longer-term human study adds more nuance
A separate, longer-duration study looked at NR's effects using a twin-pair design: 20 body-mass-index-discordant identical twin pairs took an escalating dose of NR (250 to 1,000 mg/day) for 5 months — considerably longer than the 12-week trials above. This study found NR improved systemic NAD+ metabolism, increased muscle mitochondrial number, and beneficially altered gut microbiota composition in both leaner and heavier co-twins. However, the researchers were explicit that NR did not ameliorate adiposity or metabolic health markers overall — a second independent confirmation that raising NAD+ levels and improving certain cellular metrics doesn't reliably translate into the blood-sugar and weight outcomes that actually define diabetes risk. The twin design is notable because it controls for genetic background, making the null result on metabolic health harder to attribute to individual variation alone.
What this means if you have type 2 diabetes
The honest picture is: NAD+ precursors have not been shown, in a population resembling type 2 diabetes, to meaningfully move the needle on insulin sensitivity. If you're managing diagnosed diabetes, that management should continue to run through your physician — medication, diet, and monitoring plans that are individually tailored and evidence-backed for your specific case. A supplement with unresolved human efficacy data shouldn't substitute for or delay that. For general metabolic wellness questions outside a diabetes diagnosis, our broader look at NAD+ and metabolism covers glucose and insulin sensitivity findings in a non-diabetic context, and NAD+ and diabetic neuropathy covers the nerve-related complication research specifically.
FROM NUVIROX
Because of the caveats above, we'd encourage you to read this as general background rather than a treatment plan. If you're curious about the ingredient at the center of this research, here's what's in ours, alongside clinician-routing guidance for anything beyond everyday support:
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials
- 150 mg trans-resveratrol + 50 mg quercetin — polyphenols studied alongside NAD+ pathways for cellular health support
- 10 mg fenugreek galactomannans to support absorption
- Backed by a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
Frequently asked questions
Can NAD+ supplements lower blood sugar?
The most relevant human trial, in obese insulin-resistant men, did not find a significant effect on insulin sensitivity despite confirmed NAD+ increases. Don't expect a measurable blood-sugar change based on current evidence.
Why do mouse studies look so much better than human trials?
Mice in these studies were often on controlled high-fat diets with induced diabetes, dosed relative to body weight at levels difficult to replicate proportionally in humans, and studied over defined short windows. Translation from rodent metabolic studies to human trials frequently underperforms initial expectations — this is a broader, well-known pattern in nutrition science.
Is it safe to take an NAD+ supplement alongside diabetes medication?
This is a question for your prescribing physician, since interactions and monitoring needs vary by medication. Don't make that call without them.
Does quercetin or resveratrol in NAD+ formulas affect blood sugar?
These polyphenols have been studied in various metabolic contexts, but in Nuvirox's formula they're included as ingredients studied alongside NAD+ pathways for general cellular health, not as blood-sugar-specific agents, and we don't make that claim.
Did the 5-month twin study find any metabolic benefit at all?
It found improvements in muscle mitochondrial number and gut microbiota composition, but the researchers were explicit that adiposity and overall metabolic health markers were not improved — an important distinction between cellular-level change and the outcomes that actually define diabetes risk.
How long do these trials typically last?
Most human NR trials in this area have run 8 to 12 weeks, with the twin study extending to 5 months. Diabetes and insulin resistance often develop over years, so even the longer trials may not capture effects that take longer to emerge.
The bottom line: the diabetes hypothesis for NAD+ precursors is compelling in mice and unresolved in the human population it matters most for. That's not a reason to panic — it's a reason to keep blood sugar management where it belongs, with your care team, while treating this supplement category as still under investigation.
References
- Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-353. PMID: 29992272.
- Dollerup OL, Trammell SA, Hartmann B, et al. Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. J Clin Endocrinol Metab. 2019;104(11):5703-5714.
- Trammell SAJ, et al. Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice. Sci Rep. 2016;6:26933. PMC4882590.
- Xue Y, Shamp T, Gowda GAN, et al. A Combination of Nicotinamide and D-Ribose (RiaGev) Is Safe and Effective to Increase NAD+ Metabolome in Healthy Middle-Aged Adults. Nutrients. 2022;14(11):2219. PMC9183138.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.